Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,413 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
41/100
Introdução: A Doença de Alzheimer (DA) é uma das principais causas de demência em todo o mundo, prejudicando a vida de milhões de pessoas.
Why it matters
This integrative review analyzes scientific evidence on the use of blood biomarkers for early diagnosis of Alzheimer's disease. It is about diagnosis, not treatment, and does not demonstrate any cure or prevention.
-
Este ensayo tiene como objetivo analizar la eficacia del lecanemab como terapia modificadora de la enfermedad de Alzheimer (EA).
Why it matters
This literature review aims to analyse the efficacy of lecanemab as a disease-modifying therapy for Alzheimer's disease. No results or conclusions are provided in the available text.
-
41/100
Older adults with Alzheimer's disease (AD) frequently present to emergency departments (EDs) with multiple coexisting conditions.
Why it matters
This cross-sectional analysis of emergency department visits identified different patterns of coexisting conditions in people with Alzheimer's disease by age group. It describes emergency presentations and multimorbidity, not any treatment, cure, or prevention.
-
ε4 noncarriers and those with lower baseline amyloid burden.
Why it matters
This single-site real-world report describes lecanemab safety and effectiveness, noting two peaks of ARIA-E at about 10 and about 25 weeks that support ongoing MRI monitoring. No marker reliably predicted ARIA, and the authors call for better markers to optimize cognitive outcomes.
-
41/100
A total of 51 patients with AD, age (median: 73 years) and 53 cognitively normal subjects (median age: 69) were included.
Why it matters
In 51 patients with AD and 53 cognitively normal subjects, global cerebral blood flow did not differ between groups, but perfusion at the cortical-CSF interface was significantly lower in AD and contributed most to predicting AD probability. The authors state that further validation against established biomarkers of CSF dynamics and clearance pathways is warranted, so this is an early imaging marker finding, not a treatment or cure.
-
Anti-amyloid immunotherapy agents represent a novel and clinically significant class of humanized monoclonal antibodies designed to selectively bind and clear pathological amyloid-beta (Aβ) aggregates from the brain, thereby slowing the progression of early Alzheimer’s disease (AD).
Why it matters
This review describes anti-amyloid immunotherapy agents as humanized monoclonal antibodies that bind and clear pathological amyloid-beta aggregates from the brain, thereby slowing progression of early Alzheimer's disease. It covers regulatory considerations including amyloid biomarker confirmation and ARIA risk management for a New Drug Submission to Health Canada.
-
Among 5757 participants (21.7% Black, 20.3% Latinx, 58.1% AORE), we found lower odds of amyloid positivity in Black (odds ratio [OR]: 0.72, 95% confidence interval [CI]: 0.62-0.83) and Latinx (OR: 0.78, 95% CI: 0.67-0.91) compared to AORE.
Why it matters
This study found that amyloid PET scans were less often positive in Black and Latinx participants and more often positive in people from more deprived neighborhoods. It does not test any treatment, but the authors note the findings may matter for anti-amyloid therapies.
-
Late-life dementia has a strong heritable component.
Why it matters
This study examined how genetic risk scores for cardiometabolic diseases and the APOE risk alleles relate to dementia outcomes in a diverse stroke study population. It states that APOE ε4 is the strongest genetic risk factor for Alzheimer disease and that polygenic risk factors also play a significant role.
-
The genetic architecture of sporadic Early-Onset Alzheimer Disease (sEOAD, onset ≤65 years) remains largely unknown.
Why it matters
De novo mutations in known monogenic genes explained sporadic early-onset Alzheimer's disease in a minority of cases, and no significant burden of rare coding variants was found. Genetic risk scores distribution was more consistent with random distribution than enrichment in probands.
-
Higher serum GFAP, YKL-40, sCD14, and NfL were associat
Why it matters
In this community-based study, higher midlife serum GFAP, YKL-40, sCD14 and NfL were linked to faster cognitive decline and higher dementia rates over 29 years. These markers reflect glial dysfunction and neuronal injury rather than Alzheimer-specific pathology, and the findings are about predicting decline, not treating or preventing it.
-
The dominant research paradigm for Alzheimer's disease has focused on amyloid-beta plaqueremoval for over three decades, producing no curative therapy despite billions of dollars ofinvestment.
Why it matters
The paper proposes the Redirection Hypothesis, which reinterprets amyloid accumulation as a late downstream consequence of upstream biological failures rather than the cause of Alzheimer's disease. It is a research proposal and framework, not a tested treatment, cure, or prevention.
-
Blood-based biomarkers are increasingly used to characterize Alzheimer's disease (AD)-related pathology, yet substantial heterogeneity exists in how biomarker burden relates to cognitive performance.
Why it matters
In this cross-sectional analysis of 348 participants, grip strength modified the relationship between blood-based Alzheimer biomarkers and cognitive function. It suggests frailty and functional reserve may affect how biomarker burden relates to thinking abilities, but it does not test any treatment, cure or prevention.
-
Vascular cognitive impairment and dementia (VCID) encompasses a heterogeneous group of disorders in which cerebrovascular pathology contributes to cognitive decline.
Why it matters
This review summarizes evidence that neuroinflammation is a major mechanism in vascular cognitive impairment and dementia, and that anti-inflammatory interventions have shown therapeutic potential in experimental models. As a review of clinical and basic studies, it does not itself demonstrate a treatment, cure or prevention.
-
Alzheimer's disease is a progressive neurodegenerative disorder that significantly impacts memory, cognition, and daily functioning.
Why it matters
This paper presents NeuroCapsule, a system using convolutional neural networks on MRI scans to classify cognitive stages, plus a Digital Memory Vault for storing reminders and personal records. It reports a favorable trade-off between accuracy and computational efficiency on the OASIS dataset, but it is a detection and management tool, not a treatment, cure or prevention.
-
Individual biomarkers significantly predict decline across multiple cognitive domains.
Why it matters
In older adults without dementia, white matter hyperintensities independently predicted decline in processing speed and executive function, and interacted with amyloid PET and plasma biomarkers to predict faster cognitive decline, most strongly in episodic memory. The authors suggest that considering amyloid PET and blood-based biomarkers alongside a person's white matter hyperintensity volume may improve the prognostic value of these biomarkers.
-
This diploma thesis presents the work carried out during 6 months within the Laboratory directed by Professor Millet, written under the supervision and with the support of Dr. Benjamin Tournier and Silvia Braconi Quintaje.
Why it matters
This is a diploma thesis describing planned work in an animal model of Alzheimer's disease, so it does not yet report any treatment or cure. It aims to study the role of mitochondria and proteins such as TSPO and MPC1, but no findings on treating or preventing Alzheimer's are given.
-
The most successful amyloid-targeting treatments achieve modest plaque reduction with marginal clinical benefit and significant adverse effects.
Why it matters
The paper states that the most successful amyloid-targeting treatments achieve only modest plaque reduction with marginal clinical benefit and significant adverse effects. It offers no new treatment, cure, or prevention data of its own.
-
Perspectivas futuras O mesmo princípio de modulação glial pode ser aplicado em cenários de morte clínica (parada cardiorrespiratória).
Why it matters
This preprint proposes a hypothetical precision neuro-immune protocol for Alzheimer's based on the IL-6/IL-10 ratio and 40Hz/10Hz stimulation, and discusses possible future use after cardiac arrest. It presents simulated data and future perspectives only, with no clinical results showing benefit for patients.
-
A total of 85 patients were included in the study with rare genotypes excluded from analysis (3 patients).
Why it matters
In patients with Alzheimer disease being evaluated for anti-amyloid therapy, APOE genotype was significantly associated with the number of microhemorrhages on brain imaging. No significant associations were found between APOE genotype and white matter hyperintensities, perivascular spaces, or cognitive impairment.
-
Alzheimer’s disease (AD) is the most widespread neurodegenerative disorder and a leading cause of dementia seen in clinical practice.
Why it matters
This review covers established and emerging Alzheimer's drugs, including cholinesterase inhibitors, memantine, several monoclonal antibodies, nutritional supplements, and agents targeting tau and amyloid pathways. It is a summary of existing research rather than a new trial, so it does not by itself show that any treatment cures or prevents the disease.
-
Alzheimer’s disease (AD) is a chronic neurological disease and one of the main causes of dementia in around the world.
Why it matters
This review summarizes machine learning and deep learning studies that use medical imaging and datasets such as ADNI, OASIS and AIBL to help diagnose Alzheimer's disease earlier and more accurately. It is a review of diagnostic methods and does not report a treatment, cure or prevention.
-
Among CU participants, men had lower Aβ42 and GFAP, and higher p-tau217/Aβ42.
Why it matters
Sex influenced plasma biomarker levels, classification metrics and prognostic value, though overall classification performance was similar across sexes. This is about interpreting biomarkers and enriching trials, not about treating or preventing Alzheimer's disease.
-
The purpose of this narrative review is to examine women's cognitive health and to highlight its association with four major pillars: (1) aging, (2) estrogen decline and loss, (3) diet, and (4) neuroinflammation, and their contribution to cognitive decline, with a focus on this combination to increase awareness and address the progression and potential amelioration of Alzheimer's disease (AD).
Why it matters
This narrative review examines how aging, estrogen decline, diet and neuroinflammation may contribute to cognitive decline and Alzheimer's disease in women, and raises a hypothesis about estrogen treatment during perimenopause. It contains no new data and does not demonstrate that any intervention treats, cures or prevents the disease.
-
Yearly costs of evolocumab were $6,840. Donanemab was more expensive at $32,000.
Why it matters
This cost analysis reports that donanemab costs $32,000 yearly, higher than evolocumab at $6,840 but reasonably priced compared with other drug classes. It concludes that considering longevity, overall worldwide Alzheimer future management would be too costly to be affordable.
-
In 2021, the age-standardised rates for ADOD were 694.01 (95% uncertainty intervals [UIs]: 602.88 to 794.08) for prevalence, 119.76 (95% UI: 104.96 to 135.89) for incidence, and 481.70 (95% UI: 228.79 to 1,023.96) for disability-adjusted life years (DALYs).
Why it matters
This global analysis found that the burden of Alzheimer's disease and other dementias increased from 1990 to 2021, with females carrying a higher burden than males across all age groups. It projects global prevalence will reach 124.89 million by 2046 and calls for urgent action, especially among females and in high-SDI regions.
From across this topic
10 of the 5,374 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Relationship of regional brain β-amyloid to gait speed
- Alzheimer disease blood biomarkers and cognition in midlife
- A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia
- Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice?
- Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer's disease
- Considering sex and gender in Alzheimer disease and other dementias
- The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals
- The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease
- The global research of magnetic resonance imaging in Alzheimer’s disease: a bibliometric analysis from 2004 to 2023
- NPTX2 and cognitive dysfunction in Alzheimer's Disease